Longevity

Longevity is moving beyond the domain of medical research to become a potential source of economic and strategic power. Advances in genomics, regenerative medicine, cellular reprogramming, and AI-enabled drug discovery are attracting growing private investment and government attention, even as evidence for dramatic extensions of healthy human lifespan remains limited. Against a backdrop of population ageing and declining fertility, even incremental improvements in healthspan could reshape labour markets, pension systems, healthcare demand, and national productivity.   However, longer healthy lives present a fundamental paradox. While they could expand individual freedom, preserve human capital, and create opportunities for education, creativity, and multiple careers, they could also extend working lives at the expense of personal choice, delay inheritance, compound wealth, and allow political, corporate, and scientific elites to retain influence for longer. If access to longevity interventions remains concentrated among wealthier individuals, existing inequalities could deepen across both generations and societies.   The geopolitical implications are equally significant. The United States, China, Saudi Arabia, the United Arab Emirates, and Singapore represent different approaches to building longevity research, investment, regulatory, and biotechnology capabilities. Countries that develop and deploy effective interventions could strengthen their human capital and technological competitiveness, while those lacking research infrastructure or access to advanced therapies risk greater dependence on external suppliers. The convergence of AI and biotechnology adds further concerns surrounding biological data, dual-use capabilities, cybersecurity, and the concentration of technological power.   This Special Edition identifies the signals that could indicate a transition from scientific promise to systemic change, outlines plausible future scenarios, and examines how governments can prepare. Its central argument is that the strategic consequences of longevity will depend not only on scientific progress, but also on how societies distribute additional healthy years, regulate emerging technologies, and adapt the institutions governing work, wealth, retirement, and political authority.  

At a Beijing military parade in September 2025, a hot microphone captured Russian President Vladimir Putin telling Chinese President Xi Jinping that advances in biotechnology could allow humans to continuously replace their organs, grow younger, and perhaps even achieve immortality. Xi responded that people may live to 150 years by the end of this century. The exchange was widely dismissed as eccentric small talk between aging heads of state. It was neither eccentric nor small.   Behind Putin's remarks sat a $26 billion Russian state initiative, a team of scientists working toward bioprinted human organs by 2030, and a broader pattern of powerful states and private actors treating human longevity as a strategic priority. As gene therapies, regenerative medicine, and organ replacement technologies move from laboratories toward clinical settings, a question that has received little attention begins to demand serious consideration: what happens to state power when the biological clock that has always constrained political leaders and their institutions starts to slow down?